DESSI MCENTEE, MS, DABT

✓NONCLINICAL STRATEGY
✓TOXICOLOGY STUDY EXECUTION
✓IND AUTHORING + SUBMISSION

About Dessi

Dessi is a board-certified toxicologist providing expert nonclinical safety consulting to biotech and pharma companies. She is a Diplomate of the American Board of Toxicology and holds an MS in Pharmacology and Toxicology from Michigan State University.

Dessi brings 15 years of experience spanning nonclinical strategy, toxicology study execution, and regulatory submission authoring. Her expertise covers a range of modalities — including small molecules, biologics, radiopharmaceuticals, and nanoparticles — and therapeutic areas such as oncology and immunology.

Prior to launching her consultancy, she held roles at Pfizer, Epizyme, and Q32 Bio, leading toxicology programs from early discovery through IND/CTA submission. She is also an invited speaker, published author, and active contributor to professional societies including ACT, SOT, RTC and CDISC.

Nonclinical Strategy
Nonclinical development of assets from discovery to clinic

Study Execution
End-to-end toxicology study execution and monitoring

CRO Management
Study placement, contract oversight, and Sponsor-CRO relations.

Timeline + Budget
Timeline and budget oversight in alignment with business goals

Regulatory Authoring
Authorship of nonclinical sections of INDs, waivers and regulatory responses

SEND Dataset Review
Review of SEND dataset compliance and submission-ready status

testimonials

Pfizer · Instem Information Solutions For Life™ · Epizyme · Q32 BIO · TOXISTRATEGY

dessi@toxistrategy.com

www.toxistrategy.com